Trial reportBlood advances2025
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
Trial report in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAzole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism. Post hoc analyses of the REACH2/REACH3 phase 3 trials examined the impact of these clinically relevant drug interactions on ruxolitinib treatment outcomes in patients with steroid-refractory acute GVHD (aGVHD; REACH2) and steroid-refractory/steroid-dependent chronic GVHD (cGVHD; REACH3). In REACH2, overall response rate (ORR) at day 28 was significantly higher with ruxolitinib vs best available therapy (BAT; 67.5% vs 44.3%; P = .0003) among patients who received concomitant azoles; among those who did not, day 28 ORR was 45.9% vs 28.6%, respectively. In REACH3, ORR at week 24 was significantly higher with ruxolitinib vs BAT in patients who did (46.6% vs 29.4%; P = .006) or did not receive (57.1% vs 19.4%; P < .0001) concomitant azoles. Concomitant azoles neither increased the rate of cytopenias in patients treated with ruxolitinib in REACH2/REACH3, nor affected the median dose of ruxolitinib up to day 28 in REACH2 (azoles/no azoles, 20.0 mg/d [range, 9.0-21.0]/20.0 mg/d [range, 8.4-20.0]) or week 24 in REACH3 (azoles/no azoles, 19.4 mg/d [range, 4.8-20.5]/19.9 mg/d [range, 5.5-20.0]). Patients receiving concomitant azoles were more likely to have ruxolitinib dose modifications in REACH2/REACH3, highlighting the importance of dose optimization in these patients. Overall, concomitant azole treatment was generally well tolerated and did not affect treatment outcomes with appropriate ruxolitinib dose optimization. Consistent with primary REACH2/REACH3 results, ruxolitinib provided greater clinical benefit than BAT in patients with steroid-refractory aGVHD and steroid-refractory/steroid-dependent cGVHD, irrespective of concomitant azole treatment. These trials were registered at www.ClinicalTrials.gov as #NCT02913261 (REACH2) and #NCT03112603 (REACH3).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.